Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that they have entered into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of nivolumab, Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex’s CD27 targeting investigational antibody in a Phase 1/2 study.Celldex Therapeutics, Inc. (NASDAQ:CLDX) weekly performance is 24.43%.On last trading day company shares ended up $15.74. Analysts mean target price for the company is $36.00. Celldex Therapeutics, Inc. (NASDAQ:CLDX) distance from 50-day simple moving average (SMA50) is -12.11%
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that clinical data on Iclusig® (ponatinib) and AP26113, its investigational oral inhibitor of anaplastic lymphoma kinase (ALK), will be presented at the Annual Meeting of the American Society of Clinical Oncology being held in Chicago, May 30 to June 3, 2014.Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares fell -0.30%in last trading session and ended the day on $6.65. ARIA Gross Margin is 78.90%and its return on assets is -65.80%.Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) quarterly performance is -20.17%.
13 MAY 2014 an investment community issues news alert on Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) shares moved down -0.15% in last trading session and was closed at $6.60, while trading in range of $6.56 – $6.63. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) year to date (YTD) performance is 48.98%.
MannKind (NASDAQ:MNKD) last issued its quarterly earnings data on Monday. The company reported ($0.14) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.13) by $0.01. During the same quarter last year, the company posted ($0.15) earnings per share. On average, analysts predict that MannKind will post $-0.34 earnings per share for the current fiscal year. MannKind Corporation (NASDAQ:MNKD) ended the last trading day at $7.01 Company weekly volatility is calculated as 4.94% and price to cash ratio as 38.20. MannKind Corporation (NASDAQ:MNKD showed a positive weekly performance of 13.06%.